Whilst at the AD/PD™ conference, we had the pleasure of speaking with Patrik Brundin about his talk on novel therapeutic targets for Parkinson’s disease.
Browsing: Parkinson’s disease
People who were previously housebound with Parkinson’s disease are now able to walk more freely thanks to spinal stimulation treatment.
To mark World Parkinson’s Day, we’re taking the opportunity to look back on some of the research highlights in the field over the last year.
Couldn’t attend the AD/PD™ 2019 Congress? Our Editor, Sharon Salt, provides her key highlights and takeaway messages from the event.
Researchers have discovered small molecules in sebum responsible for a unique odor in people with Parkinson’s that could be used for early diagnosis.
A groundbreaking treatment that delivers a drug directly to the brain may offer hope to restore damaged brain cells in Parkinson’s disease.
We had the pleasure of filming a joint seminar from the Michael J Fox Foundation and Abcam on biomarkers of neuroinflammation in Parkinson’s disease. Discover more about this in our video, with timepoints for each slide included.
Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
Gene therapy for disorders such as amyotrophic lateral sclerosis, Parkinson’s disease and Batten disease has seen success in animal models.
Largest study of its kind reveals that the appendix could act as a reservoir for disease-associated proteins related to Parkinson’s disease.